[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575146":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":44,"centralContacts":48,"locations":54,"responsibleParty":191,"collaborators":31,"id":193,"slug":194,"hasResults":195,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":31,"eligibilityCriteria":199,"healthyVolunteers":195,"sex":200,"minAge":201,"maxAge":31,"enrollmentInfo":202,"targetDuration":31,"studyType":205,"phases":206,"briefSummary":208,"conditions":209,"keywords":31,"overallStatus":57,"whyStopped":31,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Regimen A and C: JNJ-79635322+Daratumumab","EXPERIMENTAL","Participants who have received 1-3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) (Treatment regimen A1 and A3) will receive JNJ-79635322 along with daratumumab to establish the recommended phase 2 doses (RP2D\\[s\\]) of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Based on the study evaluation team (SET) decision, enrollment may proceed in participants with newly diagnosed multiple myeloma (NDMM) (Treatment regimens A2, A4 and C). Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.",[13,14],"Drug: JNJ-79635322","Drug: Daratumumab",{"label":16,"type":10,"description":17,"interventionNames":18},"Treatment Regimen B: JNJ-79635322+Pomalidomide","Participants who have received greater than or equal to (\\>=)1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory or \\>=2 prior lines of therapy, including a PI and lenalidomide will receive JNJ-79635322 along with pomalidomide to establish the RP2D(s) of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.",[13,19],"Drug: Pomalidomide",{"label":21,"type":10,"description":22,"interventionNames":23},"Treatment Regimen D and E: JNJ-79635322 + Daratumumab + Lenalidomide Combination","Participants with NDMM will receive JNJ-79635322 along with daratumumab and lenalidomide to establish the RP2D\\[s\\] of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.",[13,14,24],"Drug: Lenalidomide",[26,32,36,40],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","JNJ-79635322","JNJ-79635322 will be administered subcutaneously.",[9,16,21],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Daratumumab","Daratumumab will be administered subcutaneously.",[9,21],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Pomalidomide","Pomalidomide will be administered orally.",[16],{"type":27,"name":41,"description":42,"armGroupLabels":43,"otherNames":31},"Lenalidomide","Lenalidomide will be administered orally.",[21],[45],{"name":46,"affiliation":5,"role":47},"Janssen Research & Development, LLC Clinical Trial","STUDY_DIRECTOR",[49],{"name":50,"role":51,"phone":52,"phoneExt":31,"email":53},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",[55,68,77,86,95,104,115,124,133,142,153,162,171,182],{"facility":56,"status":57,"city":58,"state":31,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":31},"Monash Medical Centre","RECRUITING","Clayton","3168","Australia","AU",{"type":63,"coordinates":64},"Point",[65,66],145.11667,-37.91667,{"lat":66,"lon":65},{"facility":69,"status":57,"city":70,"state":31,"zip":71,"country":60,"countryCode":61,"cosmosGeoPoint":72,"geoPoint":76,"contacts":31},"St Vincents Hospital Melbourne","Fitzroy","3065",{"type":63,"coordinates":73},[74,75],144.97833,-37.79839,{"lat":75,"lon":74},{"facility":78,"status":57,"city":79,"state":31,"zip":80,"country":60,"countryCode":61,"cosmosGeoPoint":81,"geoPoint":85,"contacts":31},"Peter MacCallum Cancer Centre","Melbourne","3000",{"type":63,"coordinates":82},[83,84],144.96332,-37.814,{"lat":84,"lon":83},{"facility":87,"status":57,"city":88,"state":31,"zip":89,"country":60,"countryCode":61,"cosmosGeoPoint":90,"geoPoint":94,"contacts":31},"Calvary Mater Newcastle Hospital","Waratah","2298",{"type":63,"coordinates":91},[92,93],151.72647,-32.90667,{"lat":93,"lon":92},{"facility":96,"status":57,"city":97,"state":31,"zip":98,"country":60,"countryCode":61,"cosmosGeoPoint":99,"geoPoint":103,"contacts":31},"Wollongong Hospital","Wollongong","2500",{"type":63,"coordinates":100},[101,102],150.89345,-34.424,{"lat":102,"lon":101},{"facility":105,"status":57,"city":106,"state":31,"zip":107,"country":108,"countryCode":109,"cosmosGeoPoint":110,"geoPoint":114,"contacts":31},"Carmel Medical Center","Haifa","3436212","Israel","IL",{"type":63,"coordinates":111},[112,113],34.99928,32.81303,{"lat":113,"lon":112},{"facility":116,"status":57,"city":117,"state":31,"zip":118,"country":108,"countryCode":109,"cosmosGeoPoint":119,"geoPoint":123,"contacts":31},"Hadassah Medical Center","Jerusalem","9112001",{"type":63,"coordinates":120},[121,122],35.21633,31.76904,{"lat":122,"lon":121},{"facility":125,"status":57,"city":126,"state":31,"zip":127,"country":108,"countryCode":109,"cosmosGeoPoint":128,"geoPoint":132,"contacts":31},"Sheba Medical Center","Ramat Gan","52621",{"type":63,"coordinates":129},[130,131],34.81065,32.08227,{"lat":131,"lon":130},{"facility":134,"status":57,"city":135,"state":31,"zip":136,"country":108,"countryCode":109,"cosmosGeoPoint":137,"geoPoint":141,"contacts":31},"Tel Aviv Sourasky Medical Center","Tel Aviv","64239",{"type":63,"coordinates":138},[139,140],34.78057,32.08088,{"lat":140,"lon":139},{"facility":143,"status":57,"city":144,"state":31,"zip":145,"country":146,"countryCode":147,"cosmosGeoPoint":148,"geoPoint":152,"contacts":31},"VU Medisch Centrum","Amsterdam","1081 HV","Netherlands","NL",{"type":63,"coordinates":149},[150,151],4.88969,52.37403,{"lat":151,"lon":150},{"facility":154,"status":57,"city":155,"state":31,"zip":156,"country":146,"countryCode":147,"cosmosGeoPoint":157,"geoPoint":161,"contacts":31},"Universitair Medisch Centrum Groningen","Groningen","9713 GZ",{"type":63,"coordinates":158},[159,160],6.56667,53.21917,{"lat":160,"lon":159},{"facility":163,"status":57,"city":164,"state":31,"zip":165,"country":146,"countryCode":147,"cosmosGeoPoint":166,"geoPoint":170,"contacts":31},"UMC Utrecht","Utrecht","3584 CX",{"type":63,"coordinates":167},[168,169],5.12222,52.09083,{"lat":169,"lon":168},{"facility":172,"status":57,"city":173,"state":31,"zip":174,"country":175,"countryCode":176,"cosmosGeoPoint":177,"geoPoint":181,"contacts":31},"Hosp. Clinic de Barcelona","Barcelona","08036","Spain","ES",{"type":63,"coordinates":178},[179,180],2.15899,41.38879,{"lat":180,"lon":179},{"facility":183,"status":57,"city":184,"state":31,"zip":185,"country":175,"countryCode":176,"cosmosGeoPoint":186,"geoPoint":190,"contacts":31},"Hosp Clinico Univ de Salamanca","Salamanca","37007",{"type":63,"coordinates":187},[188,189],-5.66388,40.96882,{"lat":189,"lon":188},{"type":192,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100575146","phase-1-a-study-of-jnj-79635322-in-combination-with-daratumumab-with-or-without-lenalidomide-or-in-combination-with-pomalidomide-for-multiple-myeloma-100575146",false,"NCT06768489","A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma","A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma","Inclusion Criteria:\n\n* Have documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria\n* Meet treatment regimen-specific requirements as follows: Treatment regimen A (JNJ-79635322+daratumumab):Treatment regimens A1 and A3: Have been treated with 1 to 3 prior lines of therapy, including a proteasome inhibitor (PI) and an inhibitor, immunomodulatory drug (IMiD) therapy for the treatment of multiple myeloma (MM); Treatment regimens A2 and A4: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments; Treatment regimen B (JNJ-79635322+pomalidomide): Have received greater than or equal to (\\>=) 1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory OR \\>=2 prior lines of therapy, including a PI and lenalidomide; Treatment Regimens C, D, and E: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments\n* Have a weight \\>=40 kilograms\n* Must have an Eastern Cooperative Oncology Group status of 0 or 2\n* Have measurable disease at screening as defined by at least 1 of the following: a) Serum monoclonal protein (M-protein) level \\>= 0.5 gram per deciliter (g\u002FdL); or b) Urine M-protein level \\>=200 milligram (mg)\u002F24 hours; or c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) \\>= 10 mg\u002FdL and abnormal serum Ig kappa lambda FLC ratio. d) For participants without measurable disease in the serum, urine, or involved FLC: presence of 1 or more focus of extramedullary disease which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion \\>=2 centimeter (cm) (at its greatest dimension) diameter on whole body positron emission tomography-computed tomography (or whole-body magnetic resonance imaging approved by sponsor), and not previously radiated\n\nExclusion Criteria:\n\n* Any serious underlying medical conditions, such as: a) Evidence of active viral, bacterial, or systemic fungal infection requiring ongoing antiviral, antibacterial, or antifungal treatment. b) Active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before start of study treatment. c) Cardiac conditions (myocardial infarction, unstable angina, or coronary artery bypass graft \\\u003C=6 months prior to enrollment; New York heart association stage III or IV congestive heart failure et cetera)\n* Prior antitumor therapy as follows, in the specified time frame prior to the first dose of study treatment: a) Targeted therapy, epigenetic therapy, monoclonal antibody (mAb) treatment, or treatment with an investigational drug or an invasive investigational medical device within 21 days or 5 half-lives, whichever is less. b) Gene-modified adoptive cell therapy (example, chimeric antigen receptor \\[CAR\\] modified T cells, natural killer cells) within 90 days. c) Prior anti-CD38 directed therapy within 90 days (for treatment regimens A, C, D and E only; within 21 days for treatment regimen B). d) Conventional chemotherapy within 21 days. e) PI therapy within 14 days. f) Immunomodulatory agent therapy within 7 days. g) Radiotherapy within 14 days\n* Stem cell transplantation: a) Allogeneic stem cell transplant within 6 months before the first dose of study treatment. b) Received an autologous stem cell transplant less than or equal to (\\\u003C=)12 weeks before the first dose of study treatment\n* Nonhematologic toxicity from prior anticancer therapy that has not resolved to baseline level or to grade \\\u003C=1 (except alopecia, tissue post-RT fibrosis \\[any grade\\] or peripheral neuropathy grade \\\u003C=3)\n* Prior treatment with CD3-redirecting therapy\n* The following medical conditions: pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation, human immunodeficiency (HIV) infection, active hepatitis B or C infection, stroke or seizure within 6 months prior to first dose of study treatment","ALL","18 Years",{"count":203,"type":204},140,"ESTIMATED","INTERVENTIONAL",[207],"PHASE1","The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \\[RP2Ds\\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).",[210],"Multiple Myeloma","2026-06-19",{"date":213,"type":214},"2026-06-24","ACTUAL",{"date":216,"type":214},"2024-12-04",{"date":218,"type":204},"2029-01-02",{"name":5,"class":6},14]